The acute and transient decrease of endogenous ANXA1 let us speculate that the protection of ANXA1 may be abrogated in some reason at the early stage of cerebral I/R injury, and upregulation of ANXA1 may therefore have adjunct therapeutic benefits for AIS patients who achieved successful recanalization. This evidence concerns the gene ANXA1 and androgen insensitivity syndrome.